Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pearson claims

This article was originally published in The Tan Sheet

Executive Summary

FDA will make a final determination by Oct. 10 on the four proposed health claims, CFSAN says in a July 14 update on its 2000 program priorities. In light of the impending deadline, the Pearson plaintiffs say they are withdrawing their appeal of a D.C. federal judge's decision denying their motion to force the agency to allow immediate use of the four claims with appropriate disclaimers (1"The Tan Sheet" June 5, p. 14). CFSAN also announces a Nov. 24 deadline for determining whether health claims with qualifying disclaimers may be made for vitamin E/heart disease and vitamin B/vascular disease. The agency previously denied the two claims, finding they did not meet its significant scientific agreement standard (2"The Tan Sheet" Jan. 24, p. 10)

You may also be interested in...

Pearson Injunction Against FDA Denied By Federal Judge

A preliminary injunction against FDA requested by the Pearson v. Shalala plaintiffs was denied May 24 by D.C. federal court judge Gladys Kessler. An appeal was filed May 26 by Emord & Associates (Washington, D.C.).

Vitamin E Health Claim Falls Short Of Significant Scientific Agreement - FDA

FDA has determined a health claim relating vitamin E to a reduced risk of heart disease does not meet the "significant scientific agreement" standard. The agency's decision is articulated in a Jan. 11 letter to the Washington, D.C. firm Emord & Associates, which submitted the claim petition on behalf of Julian Whitaker, MD, Durk Pearson, Sandy Shaw and others.

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts